FOLH1 and glioblastoma: ,39 As potential pitfall for patient selection, it should be noted that (treatment-related) inflammation may also cause uptake of PSMA-based radioligands, as shown in patients with varying diseases (including nine glioblastoma cases) and rats using [68Ga]Ga-PSMA and [18F]F-DCFPyl.40, 41, 42 Future studies should validate these findings in patients with brain tumours and which, for instance MRI, parameters may guide differentiation and patient selection.